There are only about a dozen or so FDA approved rapid Flu tests in the US at the moment.
So lets say LDX could get roughly 5% of the market then that would still be somewhere around $100 billion USD a year in annual revenue.
Even at a fraction of that it brings in another revenue stream helping with the Lumos bottom line and cash flow.
Rapid Influenza Diagnostic Tests (RIDTs) | CDC
Ann: FDA Grants EUA for ViraDx, page-73
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.7¢ |
Change
-0.001(2.63%) |
Mkt cap ! $20.83M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.8¢ | 3.7¢ | $33.89K | 909.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 857775 | 3.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.8¢ | 226848 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| LDX (ASX) Chart |